The Clinical Spectrum of Antiphospholipid Syndrome

Hematology/Oncology Clinics of North America

Volumn 22, Issue 1, 2008, Pages 33-52

  Baker Jr , William F ^a,b,c   Bick, Rodger L ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Clinical Thrombosis Center   (United States)

^c KERN MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; COCAINE; FANSIDAR; HYDRALAZINE; INTERFERON; PHENYTOIN; PROCAINAMIDE; QUINIDINE;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG INDUCED DISEASE; FETUS DEATH; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; KIDNEY DISEASE; LABORATORY TEST; LUNG DISEASE; MICROANGIOPATHY; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SEROLOGY; SKIN DISEASE; TERMINAL DISEASE; VEIN THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTOPENIA; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 38349065039     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.10.007     Document Type: Review

References (97)

1. Hughes G., Harris E.N., and Gharavi A. The anticardiolipin syndrome. J Rheumatol 13 (1986) 486-489
2. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 10 (2002) 752-763
3. Roubey R.A.S. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 39 (1996) 1444-1454
4. Wilson W., Gharavi A., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
5. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
6. Provenzale J.M., Ortel T., and Allen N. Systemic thrombosis in patients with antiphospholipid syndrome: lesion distribution and imaging findings. Am J Roentgenol 170 (1998) 285-290
7. Asherson R., Khamashta M., Ordi-Rios J., et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68 (1989) 366-374
8. Vianna J.L., Khamashta M., Ordi J., et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96 (1994) 3-9
9. Piette J.C., Wechsler B., Frances C., et al. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 20 (1993) 1802-1804
10. Alarcon-Segovia D., Deleze M., O CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68 (1989) 353-365
11. Merkel P.A., Chang Y., Pierangeli S.S., et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101 6 (1996) 576-583
12. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027
13. Krnic B., O'Connor C., Looney S., et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 157 (1997) 2101-2108
14. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev 6 2 (2006) 76-80
15. Schofield Y. Systemic antiphospholipid syndrome. Lupus 12 (2003) 497-498
16. Hughes G.R., and Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 62 12 (2003) 1127
17. Lotz B.P., Schutte C.M., Colin P.F., et al. Sneddon's syndrome with anticardiolipin antibodies-complications and treatment. S Afr Med J 83 9 (1993) 663-664
18. Gezer S. Antiphospholipid syndrome. Dis Mon 49 12 (2003) 696-741
19. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15 2 (2000) 145-151
20. Schved J., Dupuy-Fons C., Biron C., et al. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) study. Hemostasis 24 (1994) 175-182
21. Piette J.C., and Cacoub P. Antiphospholipid syndrome in the elderly: caution. [editorial]. Circulation 97 (1998) 2195-2196
22. Finazzi G., Brancaccio V., Moia M., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 100 (1996) 530-536
23. Schulman S., Svenungsson E., and Granqvist S. Group DoAS. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104 (1998) 332-338
24. Wahl D., Guillemin F., de Maistre E., et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 6 (1997) 467-473
25. Varrala O., Manttari M., Manninen V., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91 (1995) 23-27
26. Levine S.R., Salowich-Palm L., Sawaya K.L., et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28 9 (1997) 1660-1665
27. Khamashta M., Cuadrado M., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
28. Galli M., Borrelli G., Jacobsen E.M., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (Warfarin in the Anti-Phospholipid Syndrome) study. Blood 110 4 (2007) 1178-1183
29. Asherson R., Mayou S., Merry P., et al. The spectrum of livedo reticularis and anticardiolipin antibodies. J Dermatol 120 (1989) 215-221
30. Miret C., Cervera R., Reverter J.C., et al. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient "seronegative" antiphospholipid syndrome?. Clin Exp Rheumatol 15 (1997) 541-544
31. Tourbach A., Piette J.C., Iba-zizzen M., et al. The natural course of cerebral lesions in Sneddon's syndrome. Arch Neurol 54 (1997) 54-60
32. Brandt J., Triplett D.A., Alving B., et al. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74 (1995) 1185-1190
33. Pengo V., Biasiolo A., Brocco T., et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 75 (1996) 721-724
34. Roubey R., Harper M., Eisenberg R., et al. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 154 (1995) 954-960
35. Galli M., Comfurius P., Barbui T., et al. Anticoagulant activity of B2-glycoprotein-I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68 (1992) 297-300
36. Viard J.-P., Amoura Z., and Bach J.-F. Association of anti-B2 glycoprotein-I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93 (1992) 181-186
37. Meroni P.L., Ronda N., De Angelis V., et al. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: In vitro and in vivo studies. Clin Rev Allergy Immunol 32 1 (2007) 67-74
38. Parkpian V., Verasertniyom O., Vanichapuntu M., et al. Specificity and sensitivity of anti-beta(2)-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. Clin Rheumatol (Mar 2, 2007)
39. Bas de Laat H., Derksen R.H., and de Groot P.G. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 112 2 (2004) 161-168
40. Cervera R., Khamashta M.A., Font J., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72 2 (1993) 113-124
41. Rand J.H. The antiphospholipid syndrome. In: Beutler E. (Ed). Williams hematology. 6th edition (2001), McGraw-Hill, New York 1715-1733
42. Love P., and Santoro S. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 112 (1990) 682-698
43. Ruiz-Irastorza G., Egurbide M.V., Ugalde J., et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 164 1 (2004) 77-82
44. Arnout J., and Jankowski M. Antiphospholipid syndrome. Hematol J 5 Suppl 3 (2004) S1-S5
45. Moyssakis I., Tektonidou M., Vasilliou V., et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations and evolution. Am J Med 120 (2007) 636-642
46. Lammle B., Kremer Hovinga J.A., and Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 3 8 (2005) 1663-1675
47. Musa M., Nounou R., Sahovic E., et al. Fulminant thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus and phospholipid autoantibodies. Eur J Haematol 64 (2000) 433-435
48. Matsuda J., Sanaka T., Gonichi K., et al. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand-factor cleaving protease. Lupus 11 (2002) 463-464
49. Amoura Z., Costedoat-Chalimeau N., Veyradier A., et al. Thrombotic thrombocytopenic purpura with ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 50 (2004) 3260-3264
50. Rieger M., Mannucci P.M., Kremer Hovinga J.A., et al. ADAMTS-13 autoantibodies in patients with thrombotic microangiopathies and other diseases. Blood 106 (2005) 1262-1267
51. Kniaz D., Eisenberg R., Elrad H., et al. Post-partum hemolytic-uremic syndrome associated with antiphospholipid antibodies. Am J Nephrol 12 (1992) 126-133
52. Ardiles L., Olavarria F., Elgueta M., et al. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: possible pathogenetic role. Nephron 78 (1998) 278-283
53. Le Thi Thuong D., Tieulie N., Costedoat-Chalimeau N., et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 64 (2005) 273-278
54. Koenig M., Roy M., Baccot S., et al. Thrombotic microangiopathy with liver, gut and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 2 (2005) 166-168
55. Bick R., and Baker W. Anticoardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 6 (1992) 1287-1299
56. Asherson R., and Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 62 (2003) 388-393
57. Asherson R., Cervera R., and Piette J.C. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80 (2001) 355-377
58. Zuckerman E., Toubi E., Golan T., et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 72 (1995) 447-451
59. Asherson R. The catastrophic antiphospholipid syndrome. [editorial]. J Rheumatol 19 (1992) 508-512
60. Piette J.C., Cervera R., Levy R.A., et al. The catastrophic antiphospholipid syndrome-Asherson's syndrome. Ann Med Interne (Paris) 154 (2003) 195-196
61. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 3 (1998) 195-207
62. Asherson R.A. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
63. Erkan D., Cervera R., and Asherson R.A. Catastrophic antiphospholipid syndrome: Where do we stand?. Arthritis Rheum 48 12 (2003) 3320-3327
64. Kirchens C. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104 (1998) 381-385
65. Bick R., and Baker W. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 25 (1999) 333-350
66. Provenzale J.M. Anatomic distribution of venous thrombosis in patients with antiphopholipid antibody: image findings. AJR Am J Roentgenol 165 (1995) 365-368
67. Carhuapoma J., Mitsias P., and Levine S.R. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28 (1997) 2363-2369
68. Nagai S., Horie Y., Akai T., et al. Superior saggital sinus thrombosis associated with primary antiphospholipid syndrome-case report. Neurol Med Chir (Tokyo) 38 (1998) 34-39
69. Deschiens M., Conrad J., Horellou M., et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27 (1996) 1724-1729
70. Bick R., Jakway J., and Baker W. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 18 (1992) 267-274
71. Montaruli B., Borchiellini A., Tamponi G., et al. Factor V Arg-Gln mutation in patients with antiphospholipid antibodies. Lupus 5 (1996) 303-306
72. Schutt M., Kluter H., Hagedorn G., et al. Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus 7 (1998) 176-182
73. Alarcon-Segovia D., Perez-Vasquez M., Villa A., et al. Preliminary classification criteria for the antiphospholipid syndrome with systemic lupus erythematosus. Semin Arthritis Rheum 21 (1992) 275-286
74. Group APASS. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48 (1997) 91-94
75. Ames P.R., Margarita A., Sokoll K.B., et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 64 2 (2005) 315-317
76. Morton K., Gavaghan S., Kirilis S., et al. Coronary artery bypass graft failure: an autoimmune phenomenon?. Lancet 2 (1986) 1353-1357
77. Ludia C., Domenico P., Monia C., et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty?. Autoimmunity 27 (1998) 141-148
78. Kaplan S., Chartash E., Pizzarello R., et al. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 124 (1992) 1331-1338
79. Brey R.L. Management of the neurological manifestations of APS-What do the trials tell us?. Thromb Res 114 5-6 (2004) 489-499
80. Sanna G., Bertolaccini M.L., and Hughes G.R. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci 1051 (2005) 465-486
81. Carp H.J.A. Antiphospholipid syndrome in pregnancy. Curr Opin Obstet Gynecol 16 (2004) 129-135
82. Gibson G., Su W., and Pittelkow M. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 36 (1997) 970-982
83. Toubi E., Krause I., Fraser A., et al. Livedo reticularis as a marker for predicting multisystem thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 23 (2005) 499-504
84. Karmochkine, Cacoub P., Dorent R., et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 23 (1996) 286-290
85. Nochy D., Daugas E., Droz D., et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10 3 (1999) 507-518
86. Nzerue C., Hewan-Lowe K., Pierangeli S., et al. "Black swan in the kidney:" renal involvement in the antiphospholipid antibody syndrome. Kidney Int 62 (2002) 733-744
87. Dunn J., Noorily S., Petri M., et al. Antiphospholipid antibodies and retinal vascular disease. Lupus 5 (1996) 313-322
88. Galli M., Finazzi G., and Barbui T. Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Ann Med Interne (Paris) 147 Suppl 1 (1996) 24-27
89. Cuadrado M., Mujic F., Munoz E., et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 56 (1997) 194-196
90. Harris E.N., Gharavi A., U H, et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 59 (1985) 231-234
91. Diz-Kucukkaya R., Hachihanafioglu A., Yenerei E., et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98 (2001) 1760-1764
92. Atsumi T., Furukawa S., Amengual O., et al. Antiphospholipid antibody associated thrombocytopenia. Lupus 14 (2005) 499-504
93. Vivaldi P., Rossetti G., Galli M., et al. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Haemotologica 82 (1997) 345-347
94. Campos L.M.A. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 12 (2003) 820-826
95. Gattorno M., Falcini F., Ravelli A., et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus 12 6 (2003) 449-453
96. Pilarska E., Lemka M., and Bakowska A. Prothrombotic risk factors in ischemic stroke and migraine in children. Acta Neurol Scand 114 1 (2006) 13-16
97. Barlas S., and Tansel T. Antiphospholipid syndrome in a child: an insight into the pathology, identification, and means of cure. J Pediatr Surg 39 8 (2004) 1280-1282